Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 8-K (Current Report)
Date of Report: October 15, 2021
Event: Completion of a public offering of Units consisting of Common Stock and Warrants.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial performance. Specific metrics include:
- Gross Proceeds: $7,929,889
- Units Sold: 1,510,455
- Price Per Unit: $5.25
- Unit Composition: One share of Common Stock and one Warrant.
- Warrant Exercise Price: $6.30 per share.
- Over-Allotment Option: Underwriter (WallachBeth Capital LLC) granted a 45-day option for up to 226,568 additional shares and/or warrants. The underwriter exercised the option for the Warrants only.
Note: The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in equity capital and the issuance of new securities. The company raised approximately $7.9 million in gross proceeds, increasing its share count and outstanding warrant obligations.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) regarding the completion of the offering but does not contain specific forward-looking guidance or management commentary within the text provided.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard implications of a public offering and the existence of an over-allotment option.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and commissions (not explicitly stated in this text).
- Confirm the exact number of additional warrants issued upon the exercise of the over-allotment option.
- Review the attached Press Release (Exhibit 99.1) for the intended use of proceeds.
- Check subsequent filings for the impact of this capital raise on the company's cash position and burn rate.